CAR-T //
Chimeric antigen receptor (CAR-) T cells are genetically engineered T cells, redirected to bind and kill tumor cells. These T cells, taken from patients’ own (autologous) or healthy donor’s (allogenic) blood, with activation, modification, and expansion, are administered to the patients. Preparation of conventional CAR-T cells can take weeks of processing, with high cost of goods. For late-stage patients, with very limited life expectancy, long manufacturing time may compromise the medical benefits.